{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:39:30Z","timestamp":1778578770365,"version":"3.51.4"},"reference-count":23,"publisher":"American Association for Cancer Research (AACR)","issue":"10","funder":[{"name":"Cancer Research Fund","award":["16-1276-CRCDA"],"award-info":[{"award-number":["16-1276-CRCDA"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>We had previously reported short-term efficacy, immunogenicity, and safety of the BNT162b2 vaccine among cancer patients with solid tumors. We aimed to evaluate these outcomes at six months postvaccination. The study cohort comprised patients who were on treatment during vaccination and throughout six months postvaccination. Serologic tests were performed after second vaccination and six months afterward. An age-matched cohort of health care workers served as controls. Documentation of COVID-19 infection, blood tests, and imaging studies during the study period was reviewed. Participants included 154 patients and 135 controls. Six months postvaccination, 122 (79%) patients were seropositive compared with 114 (84%) controls (P = 0.32). Serology titer dramatically decreased in a similar manner in both cohorts. No COVID-19 cases were documented in controls, and one case occurred in patient cohort. All previously reported adverse effects resolved. Taken together, the pattern of immunogenicity, efficacy, and safety of BNT162b2 in patients with cancer with solid tumors at six months postvaccination resembles that of the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Evidence regarding efficacy and safety of COVID-19 vaccines in patients with cancer indicate a favorable short-term profile. Immunomodulation due to anticancer treatments may affect immunity and immunogenicity of patients with cancer to the BNT162b2 vaccine over time. Our study sheds light on these long-term outcomes and portrays a trend that resembles the general population.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 2355<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-21-1072","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:50:12Z","timestamp":1630572612000},"page":"2430-2435","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors"],"prefix":"10.1158","volume":"11","author":[{"given":"Ithai","family":"Waldhorn","sequence":"first","affiliation":[{"name":"1Division of Oncology, Rambam Health Care Campus, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Holland","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Rambam Health Care Campus, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Goshen-Lago","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Rambam Health Care Campus, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelena","family":"Shirman","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Rambam Health Care Campus, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moran","family":"Szwarcwort-Cohen","sequence":"additional","affiliation":[{"name":"2Virology Laboratory, Rambam Health Care Campus, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Reiner-Benaim","sequence":"additional","affiliation":[{"name":"3Clinical Epidemiology Unit, Rambam Health Care Campus, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Shachor-Meyouhas","sequence":"additional","affiliation":[{"name":"4General Management, Rambam Health Care Campus, Haifa, Israel."},{"name":"5Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khetam","family":"Hussein","sequence":"additional","affiliation":[{"name":"4General Management, Rambam Health Care Campus, Haifa, Israel."},{"name":"5Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Fahoum","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Rambam Health Care Campus, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avivit","family":"Peer","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Rambam Health Care Campus, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit","family":"Almog","sequence":"additional","affiliation":[{"name":"3Clinical Epidemiology Unit, Rambam Health Care Campus, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Shaked","sequence":"additional","affiliation":[{"name":"5Rappaport Faculty of Medicine, Technion, Haifa, Israel."},{"name":"6Technion-Integrated Cancer Center, Technion, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3172-7619","authenticated-orcid":false,"given":"Michael","family":"Halberthal","sequence":"additional","affiliation":[{"name":"4General Management, Rambam Health Care Campus, Haifa, Israel."},{"name":"5Rappaport Faculty of Medicine, Technion, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5839-5477","authenticated-orcid":false,"given":"Irit","family":"Ben-Aharon","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Rambam Health Care Campus, Haifa, Israel."},{"name":"5Rappaport Faculty of Medicine, Technion, Haifa, Israel."},{"name":"6Technion-Integrated Cancer Center, Technion, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"2022060711460755300_bib1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060711460755300_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2022060711460755300_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"2022060711460755300_bib4","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"2022060711460755300_bib5","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/cncr.33386","article-title":"Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies","volume":"127","author":"Desai","year":"2021","journal-title":"Cancer"},{"key":"2022060711460755300_bib6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ccell.2020.10.023","article-title":"Cancer care disparities during the COVID-19 pandemic: COVID-19 and cancer outcomes study","volume":"38","author":"Schmidt","year":"2020","journal-title":"Cancer Cell"},{"key":"2022060711460755300_bib7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.annonc.2021.04.019","article-title":"Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors","volume":"32","author":"Barri\u00e8re","year":"2021","journal-title":"Ann Oncol"},{"key":"2022060711460755300_bib8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"2022060711460755300_bib9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","article-title":"Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer","volume":"7","author":"Massarweh","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022060711460755300_bib10","article-title":"Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","author":"Thomas","year":"2021","journal-title":"medRxiv"},{"key":"2022060711460755300_bib11","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N Engl J Med"},{"key":"2022060711460755300_bib12","article-title":"Durable humoral and cellular immune responses following Ad26.COV2.S vaccination for COVID-19","author":"Barouch","year":"2021","journal-title":"medRxiv"},{"key":"2022060711460755300_bib13","first-page":"e212675","article-title":"Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022060711460755300_bib14","first-page":"NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med"},{"key":"2022060711460755300_bib15","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.lanepe.2021.100150","article-title":"Decreased infectivity following BNT162b2 vaccination: a prospective cohort study in Israel","volume":"7","author":"Regev-Yochay","year":"2021","journal-title":"Lancet Reg Heal Eur"},{"key":"2022060711460755300_bib16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jamaoncol.2021.1794","article-title":"Association of COVID-19 mRNA vaccine with ipsilateral axillary lymph node reactivity on imaging","volume":"7","author":"Adin","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022060711460755300_bib17","first-page":"e213127","article-title":"Incidence of axillary adenopathy in breast imaging after COVID-19 vaccination","author":"Robinson","year":"2021","journal-title":"JAMA Oncol"},{"key":"2022060711460755300_bib18","article-title":"Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients \u2013 a prospective cohort study","author":"Ben Zadok","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022060711460755300_bib19","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/ajt.16615","article-title":"Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus","volume":"21","author":"Grupper","year":"2021","journal-title":"Am J Transplant"},{"key":"2022060711460755300_bib20","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"2022060711460755300_bib21","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cmi.2021.04.028","article-title":"Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study","volume":"27","author":"Rozen-Zvi","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2022060711460755300_bib22","article-title":"CoVariants: SARS-CoV-2 mutations and variants of interest","author":"Hodcroft","year":"2021"},{"key":"2022060711460755300_bib23","article-title":"Protocol for conduction of COVID-19 serology tests","author":"Department of Laboratories Ministry of Health Israel"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/10\/2430\/3082326\/2430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/10\/2430\/3082326\/2430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T08:14:59Z","timestamp":1654589699000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/11\/10\/2430\/665610\/Six-Month-Efficacy-and-Toxicity-Profile-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,9,2]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-21-1072","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22539176.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22539176","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6549008","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6549008.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]}}}